It’s hard to go anywhere nowadays without hearing about the benefits of cannabidiol (can-ab-id-EYE-all), aka CBD (and often CBD oil).
It’s all over the Internet, celebrities are endorsing it left and right, and it’s made its way into everything from lattes to sports drinks to sex lube (seriously).
Sales of CBD are already thought to be north of $350 million per year, and some analysts are predicting that number will surpass $1 billion by 2020.
Proponents say this is fantastic.
While CBD is a drug that comes from the same plant as marijuana, it doesn’t get you high, doesn’t have to be inhaled (no lung damage), and it’s kinda-sorta legal (more on that in a moment).
Purported benefits include alleviating anxiety, addiction, and epilepsy, accelerating post-workout recovery, curing chronic pain and even cancer, and helping with many other psychological and physiological conditions and ailments.
Some people even go so far as to say that CBD has healing properties that’ll help you live a generally healthier and happier life.
It also taps into the desire to indulge in social taboos (drug use, in this case), making it even more appealing to young people in particular.
On the other hand, CBD isn’t without detractors who claim that it’s an unproven, understudied, and potentially dangerous new health fad.
According to the naysayers, at best CBD isn’t all it’s cracked up to be, and at worst regular use can lead to major long-term health complications.
Well, the surprising and disturbing answer is we don’t really know.
As you’ll learn in this podcast, parsing the research on CBD is about as easy as combing your hair with a broom and in the end, you’re left with far more questions than answers.
The short story on CBD is that although it may have some benefits, it’s being wildly overhyped and oversold and it most certainly poses some serious health risks.
Let’s kick the discussion off by first exploring what CBD is.
Lastly, if you want to support the show, please drop a quick review of it over on iTunes. It really helps!
Would you rather read about CBD oil? Then check out this article!
5:43 – What is CBD?
8:29 – How does our endocannabinoid system function?
11:08 – What are the benefits of CBD?
18:31 – Does CBD reduce chronic pain?
22:59 – Does CBD help with epilepsy?
27:23 – Does CBD help curb drug addiction?
30:32 – Does CBD help curb nicotine addiction?
31:59 – Does CBD help fight cancer?
33:11 – Can you get high from CBD?
36:09 – Is CBD safe?
38:02 – Is CBD legal?
39:15 – What are alternatives to CBD?
What did you think of this episode? Have anything else to share? Let me know in the comments below!
+ Scientific References
- Lu, H. C., & MacKie, K. (2016). An introduction to the endogenous cannabinoid system. In Biological Psychiatry (Vol. 79, Issue 7, pp. 516–525). Elsevier USA. https://doi.org/10.1016/j.biopsych.2015.07.028
- Stanworth, R. D., & Jones, T. H. (2008). Testosterone for the aging male; current evidence and recommended practice. In Clinical Interventions in Aging (Vol. 3, Issue 1, pp. 25–44). Dove Press. https://doi.org/10.2147/cia.s190
- Zou, S., & Kumar, U. (2018). Cannabinoid receptors and the endocannabinoid system: Signaling and function in the central nervous system. In International Journal of Molecular Sciences (Vol. 19, Issue 3). MDPI AG. https://doi.org/10.3390/ijms19030833
- Jurkus, R., Day, H. L. L., Guimarães, F. S., Lee, J. L. C., Bertoglio, L. J., & Stevenson, C. W. (2016). Cannabidiol regulation of learned fear: Implications for treating anxiety-related disorders. Frontiers in Pharmacology, 7(NOV), 454. https://doi.org/10.3389/fphar.2016.00454
- Zuardi, A. W., Rodrigues, N. P., Silva, A. L., Bernardo, S. A., Hallak, J. E. C., Guimarães, F. S., & Crippa, J. A. S. (2017). Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Frontiers in Pharmacology, 8(MAY). https://doi.org/10.3389/fphar.2017.00259
- Blessing, E. M., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015). Cannabidiol as a Potential Treatment for Anxiety Disorders. In Neurotherapeutics (Vol. 12, Issue 4, pp. 825–836). Springer New York LLC. https://doi.org/10.1007/s13311-015-0387-1
- Crippa, J. A. S., Nogueira Derenusson, G., Borduqui Ferrari, T., Wichert-Ana, L., Duran, F. L. S., Martin-Santos, R., Vinícius Simões, M., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., Santos Filho, A., Freitas-Ferrari, M. C., McGuire, P. K., Zuardi, A. W., Busatto, G. F., & Hallak, J. E. C. (2011). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report. Journal of Psychopharmacology, 25(1), 121–130. https://doi.org/10.1177/0269881110379283
- Hammell, D. C., Zhang, L. P., Ma, F., Abshire, S. M., McIlwrath, S. L., Stinchcomb, A. L., & Westlund, K. N. (2016). Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. European Journal of Pain (United Kingdom), 20(6), 936–948. https://doi.org/10.1002/ejp.818
- Klimkiewicz, A., & Jasinska, A. (2018). The health effects of cannabis and cannabinoids. Psychiatria, 15(2), 88–92. https://doi.org/10.17226/24625
- Russo, E. B. (2008). Cannabinoids in the management of difficult to treat pain. In Therapeutics and Clinical Risk Management (Vol. 4, Issue 1, pp. 245–259). Dove Press. https://doi.org/10.2147/tcrm.s1928
- Schaefer, M., Sahin, T., & Berstecher, B. (2019). Why do open-label placebos work? A randomized controlled trial of an open-label placebo induction with and without extended information about the placebo effect in allergic rhinitis. PLoS ONE, 13(3). https://doi.org/10.1371/journal.pone.0192758
- Hróbjartsson, A., Kaptchuk, T. J., & Miller, F. G. (2011). Placebo effect studies are susceptible to response bias and to other types of biases. Journal of Clinical Epidemiology, 64(11), 1223–1229. https://doi.org/10.1016/j.jclinepi.2011.01.008
- Perucca, E. (2017). Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last? Journal of Epilepsy Research, 7(2), 61–76. https://doi.org/10.14581/jer.17012
- Sulak, D., Saneto, R., & Goldstein, B. (2017). The current status of artisanal cannabis for the treatment of epilepsy in the United States. Epilepsy and Behavior, 70(Pt B), 328–333. https://doi.org/10.1016/j.yebeh.2016.12.032
- Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout, R., Scheffer, I. E., Thiele, E. A., & Wright, S. (2017). Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. New England Journal of Medicine, 376(21), 2011–2020. https://doi.org/10.1056/NEJMoa1611618
- J French, E Thiele, M Mazurkiewicz-Beldzinska, S Benbadis, E Marsh, C Joshi, C Roberts, A Taylor, & K Sommerville. (n.d.). Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): Results of a multi-center, randomized, double-blind, placebo controlled trial. Retrieved October 19, 2020, from https://www.mdlinx.com/internal-medicine/conference-abstract.cfm/61285/?nonus=0&searchstring=&coverage_day=0&page=1
- Devinsky, O., Patel, A. D., Cross, J. H., Villanueva, V., Wirrell, E. C., Privitera, M., Greenwood, S. M., Roberts, C., Checketts, D., VanLandingham, K. E., & Zuberi, S. M. (2018). Effect of cannabidiol on drop seizures in the lennox–gastaut syndrome. New England Journal of Medicine, 378(20), 1888–1897. https://doi.org/10.1056/NEJMoa1714631
- Bart, G. (2012). Maintenance medication for opiate addiction: The foundation of recovery. In Journal of Addictive Diseases (Vol. 31, Issue 3, pp. 207–225). NIH Public Access. https://doi.org/10.1080/10550887.2012.694598
- Ren, Y., Whittard, J., Higuera-Matas, A., Morris, C. V., & Hurd, Y. L. (2009). Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. Journal of Neuroscience, 29(47), 14764–14769. https://doi.org/10.1523/JNEUROSCI.4291-09.2009
- Bhargava, H. N. (1976). Effect of some cannabinoids on naloxone-precipitated abstinence in morphine-dependent mice. Psychopharmacology, 49(3), 267–270. https://doi.org/10.1007/BF00426828
- Zlebnik, N. E., & Cheer, J. F. (2016). Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation? Annual Review of Neuroscience, 39, 1–17. https://doi.org/10.1146/annurev-neuro-070815-014038
- Morgan, C. J. A., Das, R. K., Joye, A., Curran, H. V., & Kamboj, S. K. (2013). Cannabidiol reduces cigarette consumption in tobacco smokers: Preliminary findings. Addictive Behaviors, 38(9), 2433–2436. https://doi.org/10.1016/j.addbeh.2013.03.011
- Veiga, M., Costa, E. M., Silva, S., & Pintado, M. (2020). Impact of plant extracts upon human health: A review. In Critical Reviews in Food Science and Nutrition (Vol. 60, Issue 5, pp. 873–886). Taylor and Francis Inc. https://doi.org/10.1080/10408398.2018.1540969